ATBB 22
Alternative Names: ATBB-22Latest Information Update: 04 Oct 2023
At a glance
- Originator Apcegen Technologies
- Class
- Mechanism of Action Glucagon-like peptide 1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 19 Sep 2023 No recent development for Metabolic disorders in India (unspecified route)
- 18 Sep 2023 Early research in Metabolic disorders in India prior to September 2023 (unspecified route) (Apcegen Technologies pipeline, September 2023)